Eupraxia Pharmaceuticals (NASDAQ:EPRX) Issues Earnings Results

Eupraxia Pharmaceuticals (NASDAQ:EPRX) announced its earnings results on Tuesday. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02, Zacks reports.

Eupraxia Pharmaceuticals Trading Up 0.6%

NASDAQ EPRX traded up $0.04 during trading on Tuesday, hitting $6.70. The company had a trading volume of 181,022 shares, compared to its average volume of 269,418. The company has a current ratio of 19.31, a quick ratio of 19.31 and a debt-to-equity ratio of 0.02. Eupraxia Pharmaceuticals has a one year low of $5.04 and a one year high of $9.32. The company has a market cap of $435.63 million, a price-to-earnings ratio of -6.38 and a beta of 1.08. The company’s fifty day moving average is $6.40 and its 200-day moving average is $7.20.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

A number of institutional investors have recently bought and sold shares of EPRX. Vivo Capital LLC purchased a new stake in Eupraxia Pharmaceuticals in the third quarter worth about $7,965,000. Ikarian Capital LLC purchased a new position in shares of Eupraxia Pharmaceuticals in the 4th quarter valued at approximately $4,606,000. Squadron Capital Management LLC purchased a new position in shares of Eupraxia Pharmaceuticals in the 4th quarter valued at approximately $3,775,000. Velan Capital Investment Management LP bought a new stake in shares of Eupraxia Pharmaceuticals during the third quarter valued at approximately $2,077,000. Finally, Royal Bank of Canada boosted its position in shares of Eupraxia Pharmaceuticals by 21.1% during the first quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock valued at $1,125,000 after purchasing an additional 59,683 shares in the last quarter.

Wall Street Analysts Forecast Growth

EPRX has been the subject of a number of analyst reports. Zacks Research raised Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Thursday, May 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, July 15th. Wall Street Zen cut shares of Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Eupraxia Pharmaceuticals in a research report on Monday, May 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.